Myocardial Fibrosis and Cardiomyopathy Risk: A Genetic Link in the MESA

Mahsima Shabani1, Min Wang2, Gregory D Jenkins3

  • 1Division of Cardiology, Department of Medicine (M.S., J.A.C.L.), Johns Hopkins University School of Medicine, Baltimore, MD.

PubMed

Insights

Genetic variants in SMARCB1 are linked to increased myocardial fibrosis, a key factor in cardiomyopathies. This finding may reveal a new pathway connecting genetic risk to heart disease development.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Common genetic variants influence hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) risk.
  • These variants are also linked to left ventricular (LV) traits.
  • The association between these genetic variants and myocardial fibrosis, a key mediator of cardiomyopathy, remains unclear.

Purpose of the Study:

  • To investigate the association between common genetic variants and myocardial fibrosis.
  • To explore the role of these variants in extracellular volume, a marker of myocardial fibrosis.
  • To examine the functional impact of identified variants on gene expression and fibrosis-related pathways.

Main Methods:

  • Utilized data from the Multi-Ethnic Study of Atherosclerosis (N=1255) with cardiac MRI and genotyping.
  • Regressed log extracellular volume on 50 candidate single nucleotide polymorphisms (SNPs) associated with cardiomyopathy and LV traits.
  • Performed fixed-effect meta-analyses for ancestry-specific results and conducted gene knockdown experiments in human cardiac fibroblasts.

Main Results:

  • The SMARCB1 rs2186370 variant, associated with HCM and DCM risk, showed a significant association with increased extracellular volume (P=0.0002).
  • The SMARCB1 rs2070458 locus, linked to LV wall thickness and mass, was also significantly associated with increased extracellular volume (P=0.0002).
  • SMARCB1 variants are expression quantitative loci in human LV tissue, decreasing SMARCB1 expression and leading to increased TGF-β1-mediated fibrosis markers in vitro.

Conclusions:

  • Common genetic variation in SMARCB1 is associated with increased myocardial fibrosis, assessed by cardiac MRI.
  • These findings suggest a potential pathophysiological link between SMARCB1 variants, myocardial fibrosis, and cardiomyopathy risk.
  • Further research is needed to confirm if these genetic associations translate to a direct pathophysiological link in cardiomyopathy development.
Abstract

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
9
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
15
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16